MedTrace Logo

ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

NCT02616497 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1220

Last updated 2018-04-17

No results posted yet for this study

Summary

Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients with stable coronary artery disease (CAD) and in those with a history of an acute non-cardioembolic ischemic stroke.

Conditions

  • Atherothrombosis

Interventions

DRUG

Aspirin

COX-1 inhibitor

DRUG

Triflusal

COX-1 inhibitor

Sponsors & Collaborators

  • University of Ioannina

    lead OTHER

Principal Investigators

  • Alexandros Tselepis, MD · Atherothrombosis Research Centre

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-02-28
Completion
2018-03-28

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02616497 on ClinicalTrials.gov